Cancers · 2023 · 19 citations · 61 references
MedicineCancer BiologyOncologyCell SignalingMolecular OncologySignal TransductionCancer Cell SignalingGrowth Factor SignalingOncogenic Signaling PathwaysRas Family OncogenesReceptor Tyrosine Kinase SignalingSignal Transduction In CancerAlk InhibitionAlk Point MutationsAnaplastic Lymphoma Kinase InhibitionDownstream Ras-mapk PathwayInsulin-like Growth Factor-1Phosphatidylinositol 3-Kinase-akt PathwayPi3k-akt Signaling PathwayRas-mitogen-activated Protein Kinase Signaling
Aberrant activation of anaplastic lymphoma kinase (ALK) by activating point mutation or amplification drives 5–12% of neuroblastoma (NB). Previous work has identified the involvement of the insulin-like growth factor 1 receptor (IGF1R) receptor tyrosine kinase (RTK) in a wide range of cancers. We show here that many NB cell lines exhibit IGF1R activity, and that IGF1R inhibition led to decreased cell proliferation to varying degrees in ALK-driven NB cells. Furthermore, combined inhibition of ALK and IGF1R resulted in synergistic anti-proliferation effects, in particular in ALK-mutated NB cells. Mechanistically, both ALK and IGF1R contribute significantly to the activation of downstream PI3K-AKT and RAS-MAPK signaling pathways in ALK-mutated NB cells. However, these two RTKs employ a differential repertoire of adaptor proteins to mediate downstream signaling effects. We show here that ALK signaling led to activation of the RAS-MAPK pathway by preferentially phosphorylating the adaptor proteins GAB1, GAB2, and FRS2, while IGF1R signaling preferentially phosphorylated IRS2, promoting activation of the PI3K-AKT pathway. Together, these findings reveal a potentially important role of the IGF1R RTK in ALK-mutated NB and that co-targeting of ALK and IGF1R may be advantageous in clinical treatment of ALK-mutated NB patients.
61
Identification of ALK as a major familial neuroblastoma predisposition gene
Yaël P. Mossé, Marci Laudenslager, Luca Longo et al. · Nature · 2008 · 1.4K citations
Oncogenic mutations of ALK kinase in neuroblastoma
Yuyan Chen, Junko Takita, Young Lim Choi et al. · Nature · 2008 · 914 citations
Activating mutations in ALK provide a therapeutic target in neuroblastoma
Rani E. George, Takaomi Sanda, Megan Hanna et al. · Nature · 2008 · 892 citations · Full text